-
Global Biotechnology & Pharmaceutical Markets2 weeks agoWebinar: The China question: Can US biotechs lead as investment heads east?
In this webinar, BioSpace will gathered experts to discuss China’s impact on the future of biotech and how both U.S. and Chinese companies can thrive—and maybe...
-
Global Biotechnology & Pharmaceutical Markets2 weeks agoSTAT+: Trump administration delays new rule that could restrict imported medicines from Canada and overseas
The Trump administration is delaying by 90 days a federal rule that could prevent Americans from obtaining prescription drugs from licensed international pharmacies.
-
Global Biotechnology & Pharmaceutical Markets2 weeks agoSTAT+: Pharmalittle: We’re reading about Sanofi settling an EU antitrust probe, ‘pharma bro’ Shkreli, and more
The FTC asked a U.S. court to hold Martin Shkreli in contempt for “flagrantly” violating a court order banning him from working in the pharma industry
-
Global Biotechnology & Pharmaceutical Markets2 weeks agoVerdiva ends mid-stage study of oral GLP-1 amid ‘market evolution’
The candidate is an oral version of ecnoglutide, a subcutaneous formulation of which is approved in China for type 2 diabetes and weight management. Pfizer owns...
-
Global Biotechnology & Pharmaceutical Markets2 weeks agoSTAT+: Sanofi avoids fine as EU accepts offer to end antitrust probe over disparaging rival vaccine
E.U. antitrust regulators accepted concessions from Sanofi to settle a probe into an allegedly “misleading” campaign that disparaged a rival flu vaccine.
-
Global Biotechnology & Pharmaceutical Markets2 weeks agoSanofi escapes fine in EU mismarketing case
Sanofi will not be fined for disparaging an influenza vaccine sold by rival CSL in a marketing campaign, according to the European Commission.
-
Global Biotechnology & Pharmaceutical Markets2 weeks agoEuropean biotech leaders split on US-China fight for deal dominance, survey finds
While industry leaders are unsure whether the U.S. or China will prevail, they are largely united in the belief that Europe is lagging behind.
-
Global Biotechnology & Pharmaceutical Markets2 weeks agoRetracted Study on Helminth Infection Models Pulled After Unverifiable References Surface
PLOS Neglected Tropical Diseases has retracted a 2025 study on country-level indices in predictive models of helminth infections in Southeast Asia after several of its references...
-
Global Biotechnology & Pharmaceutical Markets3 weeks agoIts coffers replenished, Forbion looks earlier in China
BIOCENTURY | FINANCEITS COFFERS REPLENISHED, FORBION LOOKS EARLIER IN CHINAEuropean firm has $2.6B in new funds
-
Global Biotechnology & Pharmaceutical Markets3 weeks agoTepid first days for TRex, Retension after pricing IPOs: Public Equity Report
BIOCENTURY | FINANCETEPID FIRST DAYS FOR TREX, RETENSION AFTER PRICING IPOS: PUBLIC EQUITY REPORTPlus: City, Iambic propose terms ahead of listings; Lycia files for IPO; Vaxcyte’s...
Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout
Genmab’s cancer bispecific delivers early OS win in ‘exceedingly positive’ Phase 3 readout
STAT+: HHS moves to allow compounding of some unapproved peptides
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
